// THE AXIOM STANDARD

Four checks that decide it. Four more if you want them.

4X Essential is our recommended standard: identity, purity, mass, and a sterility screen. 8X Comprehensive adds optional depth for peace of mind. Below: what each check answers, the exact methods and their validation status, and the quality system behind every report.

01
// THE AXIOM STANDARD

What we recommend, and why

Recommended

4X Essential

$195

The standard every compound should actually meet.

Identity, purity, mass, and a sterility screen. These four answer the questions that decide whether a vial is safe to trust: is it the right molecule, is it clean, is the dose real, and is it free of microbial contamination. For the overwhelming majority of vials this is the complete answer - and it is what we recommend by default.

8X Comprehensive

$595

Extra depth for peace of mind - not because you need it.

8X adds endotoxin, heavy metals, post-reconstitution stability, and a fentanyl/analog adulterant screen. Worth it when you want maximum assurance or are vetting a brand-new source - but we will not pretend a clean 4X result is somehow incomplete.

WHY WE LEAD WITH 4X

Most labs upsell a higher “X” as if more layers automatically means a safer vial. That is a marketing gimmick. A wrong, impure, under-dosed, or contaminated peptide fails at the four essentials - the extra layers rarely change the verdict. We lead with 4X because it is honest, and we offer 8X for when you want belt-and-suspenders, not because the data demands it.

The four essentials

Included in 4X Essential

Each answers one specific question. Every result identifies the sample, method, specification source, quality status, and technical reviewer.

LAYER
01

Molecular Mass Fingerprinting

LC-MS/MS (ESI+)
QUESTION
Is the expected compound present?

LC-MS/MS confirms exact monoisotopic mass and fragmentation identity, ±1 Da. Identity consistent with expected mass.

METHOD STATUSValidated in-house
LAYER
02

Homogeneity Profiling

RP-HPLC 214nm (USP 621)
QUESTION
What proportion of detected chromatographic area is the primary component?

RP-HPLC at 214nm isolates the main peak from related substances at the peptide-bond absorbance wavelength.

METHOD STATUSValidated in-house
LAYER
03

Net Peptide Mass Quantitation

Quantitative HPLC vs reference std
QUESTION
How much target peptide is present per vial?

Quantitative HPLC against a qualified reference standard, stripping moisture, salts, and counter-ions like TFA. Reported as mg per vial.

METHOD STATUSValidated in-house
LAYER
04

Sterility Screen

Rapid molecular microarray screen
QUESTION
Were viable microorganisms detected?

Rapid molecular microarray sterility screen. This is a screen, NOT a USP 71 sterility test, and we label it that way. Reported as CFU against a limit.

METHOD STATUSResearch screen

The four expanded checks

Added by 8X Comprehensive

Belt-and-suspenders depth: endotoxin, heavy metals, post-reconstitution stability, and a fentanyl/analog adulterant screen. Worth it for maximum assurance or a brand-new source, not because a clean 4X result is incomplete.

LAYER
05

Bacterial Endotoxin

Kinetic chromogenic LAL
QUESTION
What endotoxin activity was measured?

Kinetic chromogenic LAL (USP 85). Reported in EU/mL and EU/mg against a stated limit.

METHOD STATUSVerified compendial
LAYER
06

Elemental Catalytic Sweep

ICP-MS (USP 232/233)
QUESTION
Were specified elements detected, and at what levels?

ICP-MS (USP 232/233) for Pb, As, Cd, Hg at sub-ppb. Each element: result, unit, LOQ, and specification source.

METHOD STATUSVerified compendial
LAYER
07

Post-Reconstitution Stability

Forced-degradation stability
QUESTION
Are separately prepared vials consistent, and is the reconstituted solution stable?

≥3 independent vials: individual results, mean, SD, CV. Post-reconstitution pH, clarity, and 24h forced-degradation kinetics.

METHOD STATUSResearch screen
LAYER
08

Fentanyl & Analog Screen

LC-MS/MS targeted adulterant screen
QUESTION
Is the sample free of fentanyl or its analogs?

LC-MS/MS targeted screen for fentanyl and common analogs (acetylfentanyl, carfentanil, and others). A harm-reduction adulterant check reported as detected / not-detected against a method detection limit.

METHOD STATUSResearch screen
02
// METHOD STATUS MATRIX

Methods & validation status

Each row is one of the eight layers above. We identify which methods are validated in-house, which compendial procedures were verified for use, and which are research screens. This status appears beside each reported result on every COA.

Validated in-house

Method validated by Axiom for the stated analyte, matrix, and range.

Verified compendial

An established compendial procedure (e.g. USP) verified as suitable for use.

Research screen

An informative screening method, not a validated or compendial release assay.

Layer · MethodReferenceInstrumentStatusRangeLOQ
01LC-MS/MS IdentityIntact mass + MS/MSThermo Orbitrap ExplorisValidated in-house±1 DaN/A
02RP-HPLC PurityUSP 621Agilent 1260 Infinity IIValidated in-house0.1–100%0.05%
03Net Peptide ContentQuant. HPLC vs ref stdAgilent 1260 + AAA confirmValidated in-house0.1–50 mg0.01 mg
04Rapid Sterility ScreenMolecular microarray (not USP 71)Rapid detection panelResearch screen0–10⁴ CFU1 CFU
05Bacterial EndotoxinUSP 85Kinetic chromogenic LALVerified compendial0.005–50 EU/mL0.005 EU/mL
06Elemental Catalytic SweepUSP 232/233Agilent 7850 ICP-MSVerified compendial0.01–1000 ppb0.01 ppb
07Forced-Degradation StabilityPost-reconstitution kineticsHPLC time-course, pH meterResearch screen0–100% degr.0.1%
08Fentanyl & Analog ScreenTargeted LC-MS/MS adulterant screenThermo Orbitrap ExplorisResearch screendetected / not-detectedmethod detection limit
ACCREDITATION STATUS

Axiom Analytics does not currently hold ISO/IEC 17025 accreditation. Testing is conducted under a documented quality system, and the method-validation status is identified beside each reported result. This statement will be updated upon accreditation.

03
// SCOPE OF TESTING

What we test, and what we do not

Our panels are built for peptides and related compounds supplied as a lyophilized powder or an aqueous solution. If your product is not on this page, ask us before you ship it. We would rather answer a question than return a vial.

ACCEPTED

CategoryExamplesAccepted form
PeptidesBPC-157, semaglutide, tirzepatide, CJC-1295, ipamorelin, TB-500, KPV, and blends of themLyophilized powder, aqueous solution, cartridge
Peptide blendsAny combination of the peptides above
A blend is certified per component. An area percent across a blend is not a purity figure for any one of them.
Lyophilized powder, aqueous solution
Peptide hydrolysatesCerebrolysin, cerebroprotein hydrolysate
These are defined mixtures, not single molecules, so the certificate carries a molecular-weight distribution and a composition profile instead of an accurate mass and a purity percent. Tell us which preparation you sent: Cerebrolysin and the generic cerebroprotein hydrolysates have different peptide profiles, and a result from one says nothing about the other.
Lyophilized powder, aqueous solution
Amino acidsL-arginine, L-citrulline, L-methionine, L-ornithine
These respond weakly at our purity wavelength, so quantitation is by mass rather than by area percent.
Lyophilized powder, aqueous solution
Small molecules with a real chromophore5-Amino-1MQ, AICAR, SLU-PP-332, thiamine, pyridoxine, methylene blueLyophilized powder, aqueous solution, capsule
Vitamins and cofactorsMethylcobalamin and cyanocobalamin (B12), NAD+
B12 is photolabile, and the cyano and methyl forms are distinct molecules. Tell us which one you sent.
Lyophilized powder, aqueous solution
Polar small moleculesL-carnitine, choline chloride, myo-inositol
These are invisible to a reverse-phase purity method and are quantified on a separate lane.
Lyophilized powder, aqueous solution
Copper peptide complexesGHK-Cu, AHK-Cu
The copper is not held by a covalent bond and our standard purity lane strips it. These are quantified on a method that leaves the complex intact, and the copper content is reported separately.
Lyophilized powder, aqueous solution

NOT ACCEPTED

These are not judgements about the products. Each one is outside what we are licensed to receive, what our sample preparation can handle, or what our instruments can measure defensibly.

Anabolic steroids and testosterone estersNot licensed

Testosterone and its esters are Schedule III controlled substances, and we are not registered to receive or analyse them. They are also supplied in oil, which our sample preparation and columns are not set up for.

SARMs and metabolic research chemicalsMethod cannot certify it

These are non-peptide small molecules, usually oral and often suspended in oil or PEG. Our purity method reads at a wavelength chosen for the peptide bond, so a number from it would not be defensible for these.

Anything in an oil or oleaginous vehicleWrong sample form

We accept lyophilized powder, aqueous solution, suspension, capsule and cartridge. An oil vehicle needs different sample preparation, and injecting it would contaminate the column our peptide work runs on.

Cannabinoids and hemp extractsMethod cannot certify it

Cannabinoid potency is a different method on a different matrix, and it is separately regulated at state level. We do not offer it.

Prescription drugs and hormone therapiesNot licensed

We are not set up to receive finished prescription drug product. Ancillary hormone therapy compounds are outside what our panels are built to certify.

Botanical tinctures and undefined extractsNothing single to measure

An extract has no single molecular identity, so there is no accurate mass to confirm and an area percent would not mean what it appears to mean.

TESTOSTERONE AND ANABOLIC STEROIDS

We do not test testosterone or any testosterone ester, and we cannot accept a sample of one. They are Schedule III controlled substances and we are not registered to receive them. They are also supplied in oil, which needs sample preparation and column hardware our peptide work does not use. This is a firm no rather than a maybe, so that nobody ships a vial we would have to refuse on arrival.

03
// QUALITY & TRUST CENTER

Accreditation status, stated plainly

No decorative badges, no claims beyond the evidence. Here is the quality system behind every result, and exactly where we stand on accreditation.

Documented QMS

SOPs, chain-of-custody, equipment qualification, and a controlled retest policy, applied to every sample.

Method Validation

Each method states analyte, matrix, range, specificity, precision, accuracy, quantitation limit, and status.

Reference Standards

Qualified reference standards with documented traceability. Blanks, controls, and suitability checks on every run.

Independent Review

Every COA passes analyst → independent technical reviewer → release. Two pairs of eyes, signed.

Correction Policy

Amendments create a new version; prior versions are superseded but retained. Full revision history is public on verify.

Zero Conflicts

Axiom owns zero retail brands and zero inventory. We are strictly a data-verification laboratory.

Start with 4X. Add 8X only when you want it.

No conflicts of interest, no overselling. 4X Essential results typically release within 4-7 business days of sample arrival (48-hour with rush); 8X Comprehensive within 7-10 business days (4-6 business days with rush).